Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature

Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature

Abstract Background Pembrolizumab, a PD-1 inhibitor, is widely used for treating advanced cancers, including metastatic non-small cell lung cancer (NSCLC). However, its use can lead to immune-related adverse events (IRAEs), including cutaneous manifestations such as bullous pemphigoid (BP). Case pre...

Full description

Saved in:
Bibliographic Details
Main Authors: Elie S. Bterrani, Francois G. Kamar
Format: Article
Language:English
Published: Springer 2025-07-01
Series:Discover Oncology
Online Access:https://doi.org/10.1007/s12672-025-02377-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items